Olema Oncology background photo
Olema Oncology profile photo

Olema Oncology Careers, Benefits, Review

Important Note: Olema will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview.  Though we use third party tools to help with advertising our jobs, please be vigilant i...

Website Globe icon www.olema.com/careers

Photo of the Rise UserPhoto of the Rise UserPhoto of the Rise UserPhoto of the Rise UserPhoto of the Rise User
25 fans
Olema Oncology Glassdoor Company Review
4.0 Glassdoor star iconGlassdoor star iconGlassdoor star iconGlassdoor star icon Glassdoor star icon
Olema Oncology DE&I Review
No rating Glassdoor star iconGlassdoor star iconGlassdoor star iconGlassdoor star iconGlassdoor star icon
CEO of Olema Oncology
Olema Oncology CEO photo
Sean Bohen, MD, PhD
Approve of CEO
Olema Oncology Employee Reviews
Featured review

It's a great place to work

2/5/2024 -
Recommends
Positive outlook

Pros

Clinical Trial data is positive, total comp is fantastic, and thanks to their hybrid model, my life/work is balanced (in the office twice a week w/ paid parking). I feel like I am part of something BIG brewing!

Cons

no cons to share, all good.
Who We Are

Aspiring to Improve the Lives of Women with Cancer

 

Olema Oncology is a clinical-stage biopharmaceutical company developing innovative targeted therapies for women’s cancers.

 

Our goal is to transform the standard of care for women living with cancer by developing more convenient and effective therapies.

 

 Our Lead Product Candidate, palazestrant (OP-1250)

 

Palazestrant (OP-1250) is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). 

 

It is currently being evaluated as both a monotherapy and in combination with a CDK4/6 inhibitor and has been granted FDA Fast Track designation for the treatment of ER /HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.

 

“We are committed to realizing the full potential of OP-1250, which we believe has demonstrated a clear, differentiated advantage.”  Sean P. Bohen, M.D., Ph.D., President and CEO of Olema Oncology

 

Learn more about our science.

Life at Olema

Onto something big, together

 

We are made up of people who are passionate beyond measure. Each and every day, we come together to do amazing things – for each other, for science, and for women with cancer.

 

Strategically located in two large biotech hubs – San Francisco, CA and Cambridge, MA – we offer a flexible work environment and the best of both coasts

 

Our modern hybrid workplace model encourages employees to split their week between working from home and at our office, while also providing several allowances to help with both home office and commute expenses. 

 

While at the office, our teams build their camaraderie, opening the door for more authentic mentorship and career development opportunities. While at home, employees can make the most of their time – whether that’s picking up the kids from school, going on a mid-day run, or catching up on chores.

 

Through this model, we strive to offer our employees the best of both work models.

 

Join us on this journey!